German mRNA-focused biotech BioNTech is branching out from its immuno-oncology focus to explore the potential of its platforms in infectious diseases. Speaking at the sidelines of BIO-Europe 2018, Sean Marett, BioNTech’s CBO and CCO, reveals how deals signed in the second half of 2018, with Pfizer to create a new type of flu vaccine and Penn University to deliver up to 10 IND-ready infectious disease-targeted assets, will underpin the development of a second major pillar for the company.
Scrip and EBD Group|Informa 2018
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
In this week's episode: US policies in spotlight at BIO; Lilly’s Verve acquisition; UroGen’s bladder cancer approval; Ireland’s biopharma talent; and Korea proposes new AI R&D project.
Axcelead/Lotte Biologics/Kanaph and NextCure/Simcere also unveil ADC-focused pacts, plus deals involving Avata/Oceanus, GSK/Bharat Biotech, Cullinan/Genrix and more.
Many assets outperform their pre-launch sales predictions despite the frequent overestimation of forecasts within the industry. In this article, Scrip highlights several such assets and the factors that influenced their predictions.
The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.
Recent moves in the industry include changes at the top at 32 Biosciences, plus new CEOs at Idorsia, Courage Therapeutics and Oncolytics Biotech.
The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.
Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.
